AnGes AAQS 2024
AnGes AAQS
5
Ticker
4563.T
ISIN
JP3127700007
WKN
779518
AnGes ima trenutni AAQS od 5. Visoki AAQS može se smatrati pozitivnim pokazateljem da se poduzeće uspješno razvija. Investitori mogu očekivati da je poduzeće na dobrom putu da ostvaruje dobit. S druge strane, važno je usporediti AAQS dionice AnGes s ostvarenim dobitima i drugim poduzećima iste industrije. Visoki AAQS nije apsolutna garancija za pozitivnu budućnost. Samo tako možemo dobiti potpunu sliku o performansi poduzeća. Da bi bolje procijenili razvoj poduzeća, važno je usporediti AAQS s drugim poduzećima iste industrije. Generalno, investitori bi uvijek trebali razmatrati AAQS poduzeća u kontekstu s drugim financijskim pokazateljima poput dobiti, EBIT-a, Cash Flow-a i drugih kako bi donijeli obrazloženu investicijsku odluku.
AnGes Aktienanalyse
Što radi AnGes?
AnGes Inc is a Japanese biotechnology company specializing in the development and commercialization of therapies for cardiovascular, immunology, and oncology disorders. The company was founded in 1999 by experienced scientist Dr. Ryuichi Morishita. AnGes' technology is based on the use of DNA plasmids to deliver genes into human cells. This method offers a high level of control and precision in modifying genetic material, with the potential to revolutionize biotherapy. The company has conducted several successful clinical studies and acquired multiple patents related to their technology. Overall, AnGes operates in three main areas: cardiovascular medicine, oncology, and immunology. The company distributes a range of products and solutions for these fields, including therapies for heart failure, angina, cancer, and autoimmune diseases. AnGes' most well-known product currently is Collategene, used for the treatment of angina. Collategene is a therapy consisting of a combination of DNA plasmids and a special gel injected into the arteries. The gel promotes the formation of new blood vessels, supplying oxygen and nutrients to damaged tissue, supporting the repair and regeneration of the heart muscle. Another important product from AnGes is HGFgene, used to treat heart failure and chronic wounds. HGFgene contains essential growth factors that stimulate the formation of new blood vessels and tissue regeneration, potentially improving heart function. In addition to these products, AnGes also offers solutions for oncology, including a therapy called Protransgene used for pancreatic cancer treatment. Protransgene contains specific DNA plasmids that produce tumor-specific antigens and stimulate the body's immune system to fight the tumor. In immunology, AnGes has developed a technology called NFkB-decoy, with the potential to treat various inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. NFkB-decoy consists of synthetic DNA plasmids introduced into inflammatory cells, with anti-inflammatory effects. Overall, AnGes Inc. has established itself as a leading provider of biotherapeutics in Japan and is currently expanding into the US market. The company has an impressive track record in clinical research and development of innovative therapy options with the potential to improve the lives of millions of people. AnGes ist eines der beliebtesten Unternehmen auf Eulerpool.com.Česta pitanja o AnGes dionici
Aktiensparpläne nude atraktivnu mogućnost za investitore za dugoročno stvaranje imovine. Jedna od glavnih prednosti je tzv. efekt prosječenja troškova: investirajući redovito fiksni iznos u dionice ili dioničke fondove, automatski se kupuje više udjela kada su cijene niske, a manje kada su visoke. To može dovesti do povoljnijeg prosječnog cijene po udjelu tijekom vremena. Osim toga, Aktiensparpläne omogućavaju i malim investitorima pristup skupim dionicama, jer mogu sudjelovati već s malim iznosima. Redovita investicija također promiče discipliniranu strategiju ulaganja i pomaže izbjeći emocionalne odluke, poput impulzivne kupnje ili prodaje. Pored toga, investitori profitiraju od potencijalnog povećanja vrijednosti dionica kao i od isplata dividendi koje mogu biti reinvestirane, što pojačava učinak kamatnog kamata i time rast uloženog kapitala.
Andere Kennzahlen von AnGes
Naša analiza dionica AnGes Prihod uključuje važne financijske pokazatelje kao što su prihod, dobit, P/E omjer, P/S omjer, EBIT, kao i informacije o dividendi. Također, razmatramo aspekte poput dionica, tržišne kapitalizacije, dugova, vlastitog kapitala i obveza AnGes Prihod. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama nudimo opsežne analize: